{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:23:43Z","timestamp":1772929423375,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11307-025-02077-2","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T21:23:09Z","timestamp":1767043389000},"page":"37-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Bioimaging Study of 89Zr-Bintrafusp Alfa PET Scans in Patients with Advanced or Metastatic NSCLC Receiving Bintrafusp Alfa Alone or in Combination with Chemotherapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Hui K.","family":"Gan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-2489","authenticated-orcid":false,"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme J.","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodie","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander F.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"3","key":"2077_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2077_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D\u2019Amico TA, DeCamp M (2022) Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(5):497\u2013530","journal-title":"J Natl Compr Canc Netw"},{"issue":"28","key":"2077_CR3","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ et al (2019) Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37(28):2518\u20132527","journal-title":"J Clin Oncol"},{"key":"2077_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123729","author":"L Boyero","year":"2020","unstructured":"Boyero L, S\u00e1nchez-Gastaldo A, Alonso M, Noguera-Ucl\u00e9s JF, Molina-Pinelo S, Bernab\u00e9-Caro R (2020) Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12123729","journal-title":"Cancers (Basel)"},{"key":"2077_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.568059","volume":"10","author":"F Wang","year":"2020","unstructured":"Wang F, Wang S, Zhou Q (2020) The resistance mechanisms of lung cancer immunotherapy. Front Oncol 10:568059","journal-title":"Front Oncol"},{"issue":"3","key":"2077_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00432-020-03414-4","volume":"147","author":"E Nadler","year":"2021","unstructured":"Nadler E, Arondekar B, Aguilar KM, Zhou J, Chang J, Zhang X et al (2021) Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. J Cancer Res Clin Oncol 147(3):671\u2013690","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2077_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/1878-0261.13146","volume":"16","author":"JL Gulley","year":"2022","unstructured":"Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F et al (2022) Dual inhibition of TGF-beta and PD-L1: a novel approach to cancer treatment. Mol Oncol 16(11):2117\u20132134","journal-title":"Mol Oncol"},{"issue":"424","key":"2077_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J et al (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci Transl Med 10(424):eaan5488","journal-title":"Sci Transl Med"},{"issue":"10","key":"2077_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1349589","volume":"6","author":"JM David","year":"2017","unstructured":"David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C (2017) A novel bifunctional anti-PD-L1\/TGF-\u03b2 trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 6(10):e1349589","journal-title":"Oncoimmunology"},{"issue":"12","key":"2077_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ et al (2023) Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1-high advanced nsclc: a randomized, open-label, phase 3 trial. J Thorac Oncol 18(12):1731\u20131742","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2077_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/oncolo\/oyac253","volume":"28","author":"F Barlesi","year":"2023","unstructured":"Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J et al (2023) Bintrafusp alfa, a bifunctional fusion protein targeting tgf-beta and pd-l1, in patients with non-small cell lung cancer resistant or refractory to immune checkpoint inhibitors. Oncologist 28(3):258\u2013267","journal-title":"Oncologist"},{"issue":"7","key":"2077_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH et al (2020) Bintrafusp alfa, a bifunctional fusion protein targeting tgf-beta and pd-l1, in second-line treatment of patients with nsclc: results from an expansion cohort of a phase 1 trial. J Thorac Oncol: Offl Publicat Intl Associ Stud Lung Canc 15(7):1210\u20131222","journal-title":"J Thorac Oncol: Offl Publicat Intl Associ Stud Lung Canc"},{"issue":"2","key":"2077_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jtho.2023.09.1452","volume":"19","author":"EE Vokes","year":"2024","unstructured":"Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV et al (2024) Bintrafusp alfa with CCRT followed by bintrafusp alfa versus placebo with CCRT followed by durvalumab in patients with unresectable stage III NSCLC: a phase 2 randomized study. J Thorac Oncol 19(2):285\u2013296","journal-title":"J Thorac Oncol"},{"key":"2077_CR14","volume":"40","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP et al (2023) Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial. The Lancet Regional Health 40:100898","journal-title":"The Lancet Regional Health"},{"issue":"2","key":"2077_CR15","doi-asserted-by":"publisher","first-page":"07","DOI":"10.1136\/jitc-2020-000664","volume":"8","author":"BC Cho","year":"2020","unstructured":"Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E et al (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer 8(2):07","journal-title":"J Immunother Cancer"},{"issue":"13","key":"2077_CR16","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1158\/1078-0432.CCR-19-3806","volume":"26","author":"YK Kang","year":"2020","unstructured":"Kang YK, Bang YJ, Kondo S, Chung HC, Muro K, Dussault I et al (2020) Safety and tolerability of bintrafusp alfa, a bifunctional fusion protein targeting tgfbeta and pd-l1, in asian patients with pretreated recurrent or refractory gastric cancer. Clin Cancer Res 26(13):3202\u20133210","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2077_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab058","volume":"3","author":"M Khasraw","year":"2021","unstructured":"Khasraw M, Weller M, Lorente D, Kolibaba K, Lee CK, Gedye C et al (2021) Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncol Adv 3(1):vdab058","journal-title":"Neuro-Oncol Adv"},{"issue":"4","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11523-021-00810-9","volume":"16","author":"CC Lin","year":"2021","unstructured":"Lin CC, Doi T, Muro K, Hou MM, Esaki T, Hara H, Chung HC, Helwig C, Dussault I, Osada M, Kondo S (2021) Bintrafusp alfa, a bifunctional fusion protein targeting TGF\u03b2 and PD-L1, in patients with esophageal squamous cell carcinoma: results from a phase 1 cohort in Asia. Target Oncol 16(4):447\u201359","journal-title":"Target Oncol"},{"issue":"4","key":"2077_CR19","first-page":"435","volume":"16","author":"B Tan","year":"2021","unstructured":"Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D et al (2021) Bintrafusp alfa, a bifunctional fusion protein targeting tgf-beta and pd-l1, in patients with esophageal adenocarcinoma: results from a phase 1 cohort. Target 16(4):435\u2013446","journal-title":"Target"},{"issue":"9","key":"2077_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1158\/2767-9764.CRC-22-0194","volume":"2","author":"VK Morris","year":"2022","unstructured":"Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A et al (2022) Bintrafusp alfa, an anti-PD-L1:TGF-beta trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979\u2013986","journal-title":"Cancer Res Commun"},{"issue":"2","key":"2077_CR21","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1093\/oncolo\/oyac254","volume":"28","author":"A Spira","year":"2023","unstructured":"Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P et al (2023) Bintrafusp alfa: a bifunctional fusion protein targeting pd-l1 and tgf-beta, in patients with pretreated colorectal cancer: results from a phase i trial. Oncologist 28(2):e124\u2013e127","journal-title":"Oncologist"},{"issue":"5","key":"2077_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.CCR-23-1829","volume":"30","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Ghamande SA, Kasamatsu Y, Gil-Martin M, Grau-Bejar JF, Garcia-Duran C et al (2024) Phase I trial of first-line Bintrafusp alfa in patients with locally advanced or persistent\/recurrent\/metastatic cervical cancer. Clin Cancer Res 30(5):975\u2013983","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2077_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/HEP.0000000000000365","volume":"78","author":"C Yoo","year":"2023","unstructured":"Yoo C, Javle MM, Verdaguer Mata H, de Braud F, Trojan J, Raoul JL et al (2023) Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers. Hepatology 78(3):758\u2013770","journal-title":"Hepatology"},{"issue":"1","key":"2077_CR24","doi-asserted-by":"publisher","first-page":"05","DOI":"10.1136\/jitc-2020-000564","volume":"8","author":"C Yoo","year":"2020","unstructured":"Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S et al (2020) Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 8(1):05","journal-title":"J Immunother Cancer"},{"key":"2077_CR25","doi-asserted-by":"crossref","unstructured":"Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, Kudo M (2020) Phase I study of the bifunctional fusion protein bintrafusp alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety\u2010assessment cohort. The Oncologist 25(9):e1292\u2013302","DOI":"10.1634\/theoncologist.2020-0249"},{"issue":"2","key":"2077_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jitc-2020-001395","volume":"8","author":"J Strauss","year":"2020","unstructured":"Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E et al (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer 8(2):12","journal-title":"J Immunother Cancer"},{"key":"2077_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts B, Schwartz LH, Sargent D, Ford R (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u201347","journal-title":"Eur J Cancer"},{"issue":"10","key":"2077_CR28","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s00259-021-05251-0","volume":"48","author":"IJG Burvenich","year":"2021","unstructured":"Burvenich IJG, Goh YW, Guo N, Gan HK, Rigopoulos A, Cao D et al (2021) Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1\/TGF-\u03b2RII fusion protein bintrafusp alfa. Eur J Nucl Med Mol Imaging 48(10):3075\u20133088","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2077_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000965","author":"DY Oh","year":"2024","unstructured":"Oh DY, Ikeda M, Lee CK, Rojas C, Hsu CH, Kim JW et al (2024) Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: a randomized phase 2\/3 trial. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000965","journal-title":"Hepatology"},{"issue":"10","key":"2077_CR30","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s00259-021-05251-0","volume":"48","author":"IJG Burvenich","year":"2021","unstructured":"Burvenich IJG, Goh YW, Guo N, Gan HK, Rigopoulos A, Cao D et al (2021) Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1\/TGF-betaRII fusion protein bintrafusp alfa. Eur J Nucl Med Mol Imaging 48(10):3075\u20133088","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"25","key":"2077_CR31","doi-asserted-by":"publisher","first-page":"11404","DOI":"10.7150\/thno.49422","volume":"10","author":"AM Scott","year":"2020","unstructured":"Scott AM, Akhurst T, Lee FT, Ciprotti M, Davis ID, Weickhardt AJ et al (2020) First clinical study of a pegylated diabody (124)I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. Theranostics 10(25):11404\u201311415","journal-title":"Theranostics"},{"key":"2077_CR32","unstructured":"International Commission on Radiological Protection (IRCP) (2016) The ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractions. ICRP Publication 133"},{"issue":"6","key":"2077_CR33","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E (2005) OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46(6):1023\u20131027","journal-title":"J Nucl Med"},{"issue":"11","key":"2077_CR34","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.2967\/jnumed.109.065862","volume":"50","author":"PK B\u00f6rjesson","year":"2009","unstructured":"B\u00f6rjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR et al (2009) Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 50(11):1828\u20131836","journal-title":"J Nucl Med"},{"issue":"2","key":"2077_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2967\/jnumed.114.147819","volume":"56","author":"NE Makris","year":"2015","unstructured":"Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GA, Verheul HM et al (2015) PET\/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab. J Nucl Med 56(2):249\u2013254","journal-title":"J Nucl Med"},{"issue":"6","key":"2077_CR36","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","volume":"18","author":"R Laforest","year":"2016","unstructured":"Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV et al (2016) [(89)Zr]trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer. Mol Imaging Biol 18(6):952\u2013959","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"2077_CR37","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","volume":"48","author":"RIJ Merkx","year":"2021","unstructured":"Merkx RIJ, Lobeek D, Konijnenberg M, Jim\u00e9nez-Franco LD, Kluge A, Oosterwijk E et al (2021) Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging 48(10):3277\u20133285","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2077_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cac2.12244","volume":"42","author":"B Cheng","year":"2022","unstructured":"Cheng B, Ding K, Chen P, Ji J, Luo T, Guo X et al (2022) Anti-PD-L1\/TGF-betaR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1\/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond) 42(1):17\u201336","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"2077_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12253-018-0469-6","volume":"26","author":"M Evans","year":"2020","unstructured":"Evans M, O\u2019Sullivan B, Hughes F, Mullis T, Smith M, Trim N et al (2020) The clinicopathological and molecular associations of PD-L1 expression in non-small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 assay. Pathol Oncol Res 26(1):79\u201389","journal-title":"Pathol Oncol Res"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02077-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:02:13Z","timestamp":1772859733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02077-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02077-2","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CWW is listed as an inventor on patents related to radiopharmaceuticals and serves as a consultant in the radiopharmaceutical industry. HKG has previously received honoraria and been an advisor to Merck. SP has previously received honoraria from Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}